Benzinga | Mar 11, 2021 07:01AM EST

Alkermes Announces FDA Orphan Drug Designation For Nemvaleukin Alfa For Treatment Of Mucosal Melanoma

DUBLIN, March 11, 2021 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced that nemvaleukin alfa ("nemvaleukin", formerly referred to as ALKS 4230), the company's investigational engineered interleukin-2 (IL-2) variant immunotherapy, has been granted orphan drug designation for the treatment of mucosal melanoma by the U.S. Food and Drug Administration (FDA).